Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Disparities in Treatment Patterns for Pediatric Patients with Chalazion by Age, Gender, and Race/Ethnicity
Author Affiliations & Notes
  • Andrea Jasmine Arreguin
    Stony Brook University Renaissance School of Medicine, Stony Brook, New York, United States
  • Jullian James Valadez
    Vanderbilt University School of Medicine, Nashville, Tennessee, United States
  • Dolly Ann Padovani-Claudio
    Vanderbilt Eye Institute, Nashville, Tennessee, United States
  • Footnotes
    Commercial Relationships   Andrea Arreguin None; Jullian Valadez None; Dolly Padovani-Claudio None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5247. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andrea Jasmine Arreguin, Jullian James Valadez, Dolly Ann Padovani-Claudio; Disparities in Treatment Patterns for Pediatric Patients with Chalazion by Age, Gender, and Race/Ethnicity. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5247.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : A previous study found that Hispanic and Asian children develop chalazia at a higher rate than other racial/ethnic groups. This retrospective chart review evaluated age, gender, and racial/ethnic differences in prevalence and treatment of chalazia among pediatric patients.

Methods : Age, gender, race/ethnicity-based chalazia diagnosis counts (by ICD9 and ICD10 codes) and management profiles (by CPT codes or medication records) were quantified in children 2-18 years old (y/o) using the record counter in the Synthetic Derivative, our deidentified institutional health record database. Medications in the search strategy were Fluorometholone, Tobradex, Maxitrol, Blephamide, and Erythromycin. CPT 678-00,-01,-05,-08,-40, and ICD-9 08.21 codes were used to stratify by treatment. We used Fisher’s exact tests and Chi-square analyses to measure differences in prevalence and treatment modalities.

Results : Girls had 1.17 times the odds of chalazia compared to boys (95% confidence interval [CI]: 1.08-1.27, p<0.001). Hispanic children had 4.92 (CI: 4.48-5.42, p<0.0001), Asian children had 3.62 (CI: 3.00-4.37, p<0.0001) and African American children had 1.80 (CI:1.60-2.02, p<0.0001) times the odds of chalazia than Caucasian children. Of 2,296 children diagnosed with chalazion, 985 patients were managed only with prescription medications (without surgical intervention), 319 received both medicine and surgery, and 159 only received surgery. There was a significant difference in the distribution of treatment modalities based on age (Chi-square, p<0.0001). Compared to children 13-18 y/o, children between 6-12 y/o had 1.85 times the odds of receiving only medications and not surgery. Further, compared to Caucasian children, Asian children had 1.87 (CI: 1.07-3.23, p=0.02) and Hispanic children 1.34 times the odds (CI: 1.03-1.74, p=0.03) of management with medications only.

Conclusions : We identify racial/ethnic disparities in the prevalence and treatment of chalazia in pediatric patients 2-18 y/o. Compared to Caucasian children, Hispanic children had the highest odds of having chalazia and lowest odds of obtaining only surgery, while Asian children had the highest odds of receiving only prescription drug management without any surgery. Further investigation is warranted to understand the root causes of the observed disparities in the prevalence and treatment of chalazion.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×